In fact, suppression of TGF‐β will further boost the efficacy of anti‐PD‐L1 for tumour eradication in which responders to the M7824 therapy display a shift in the tumour ecosystem into a more immune‐permissive profile, as attested by single‐cell RNA sequencing of SCC.93 The gene discussed is TGFB1; the disease is neoplasm.